340 related articles for article (PubMed ID: 17507880)
1. N-acetylaspartate (NAA) levels in selected areas of the brain in patients with chronic schizophrenia treated with typical and atypical neuroleptics: a proton magnetic resonance spectroscopy (1H MRS) study.
Szulc A; Galińska B; Tarasów E; Kubas B; Dzienis W; Konarzewska B; Poplawska R; Tomczak AA; Czernikiewicz A; Walecki J
Med Sci Monit; 2007 May; 13 Suppl 1():17-22. PubMed ID: 17507880
[TBL] [Abstract][Full Text] [Related]
2. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
[TBL] [Abstract][Full Text] [Related]
3. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenic patients. A proton magnetic resonance spectroscopy (1H MRS).
Szulc A; Galinska B; Tarasow E; Dzienis W; Kubas B; Konarzewska B; Walecki J; Alathiaki AS; Czernikiewicz A
Pharmacopsychiatry; 2005 Sep; 38(5):214-9. PubMed ID: 16189748
[TBL] [Abstract][Full Text] [Related]
4. [First and second generation antipsychotics and morphological and neurochemical brain changes in schizophrenia. Review of magnetic resonance imaging and proton spectroscopy findings].
Szulc A
Psychiatr Pol; 2007; 41(3):329-38. PubMed ID: 17900049
[TBL] [Abstract][Full Text] [Related]
5. Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment.
Szulc A; Galinska B; Tarasow E; Waszkiewicz N; Konarzewska B; Poplawska R; Bibulowicz D; Simonienko K; Walecki J
Pharmacopsychiatry; 2011 Jun; 44(4):148-57. PubMed ID: 21710405
[TBL] [Abstract][Full Text] [Related]
6. Relationship between frontal N-acetylaspartate and cognitive deficits in first-episode schizophrenia.
Galińska B; Szulc A; Tarasów E; Kubas B; Dzienis W; Siergiejczyk L; Czernikiewicz A; Walecki J
Med Sci Monit; 2007 May; 13 Suppl 1():11-6. PubMed ID: 17507879
[TBL] [Abstract][Full Text] [Related]
7. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy.
Deicken RF; Zhou L; Schuff N; Fein G; Weiner MW
Biol Psychiatry; 1998 Apr; 43(7):483-8. PubMed ID: 9547926
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and neuropsychological correlates of proton magnetic resonance spectroscopy detected metabolites in brains of first-episode and schizophrenic patients].
Szulc A; Galińska B; Tarasów E; Walecki J; Dzienis W; Kubas B; Czernikiewicz A
Psychiatr Pol; 2003; 37(6):977-88. PubMed ID: 14727370
[TBL] [Abstract][Full Text] [Related]
9. Quantitative magnetic resonance spectroscopy of schizophrenia: relationship between decreased N-acetylaspartate and frontal lobe dysfunction.
Tanaka Y; Obata T; Sassa T; Yoshitome E; Asai Y; Ikehira H; Suhara T; Okubo Y; Nishikawa T
Psychiatry Clin Neurosci; 2006 Jun; 60(3):365-72. PubMed ID: 16732755
[TBL] [Abstract][Full Text] [Related]
10. [The influence of atypical antipsychotics on brain functioning in schizophrenia. A proton magnetic resonance study].
Szulc A; Galińiska B; Tarasów E; Dzienis W; Kubas B; Konarzewska B; Waszkiewicz N; Popławska R
Psychiatr Pol; 2010; 44(3):415-26. PubMed ID: 20672520
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of right thalamus and temporal cortex metabolite levels of drug-naive first-episode psychotic and chronic schizophrenia in patients].
Başoğlu C; Cetin M; Oner O; Ebrinç S; Semiz UB; Kandilcioğlu H; Silit E; Kizilkaya E
Turk Psikiyatri Derg; 2006; 17(2):85-91. PubMed ID: 16755408
[TBL] [Abstract][Full Text] [Related]
12. Duration of untreated psychosis vs. N-acetylaspartate and choline in first episode schizophrenia: a 1H magnetic resonance spectroscopy study at 4.0 Tesla.
Théberge J; Al-Semaan Y; Drost DJ; Malla AK; Neufeld RW; Bartha R; Manchanda R; Menon R; Densmore M; Schaefer B; Williamson PC
Psychiatry Res; 2004 Jul; 131(2):107-14. PubMed ID: 15313517
[TBL] [Abstract][Full Text] [Related]
13. Favorable effect on neuronal viability in the anterior cingulate gyrus due to long-term treatment with atypical antipsychotics: an MRSI study.
Braus DF; Ende G; Weber-Fahr W; Demirakca T; Henn FA
Pharmacopsychiatry; 2001 Nov; 34(6):251-3. PubMed ID: 11778146
[TBL] [Abstract][Full Text] [Related]
14. Frontal lobe of children with schizophrenia spectrum disorders: a proton magnetic resonance spectroscopic study.
Brooks WM; Hodde-Vargas J; Vargas LA; Yeo RA; Ford CC; Hendren RL
Biol Psychiatry; 1998 Feb; 43(4):263-9. PubMed ID: 9513735
[TBL] [Abstract][Full Text] [Related]
15. MRI volumetry and proton MR spectroscopy of the brain in Lafora disease.
Villanueva V; Alvarez-Linera J; Gómez-Garre P; Gutiérrez J; Serratosa JM
Epilepsia; 2006 Apr; 47(4):788-92. PubMed ID: 16650146
[TBL] [Abstract][Full Text] [Related]
16. The effect of clozapine on neuroimaging findings in schizophrenia.
Ertugrul A; Uluğ B
Psychiatr Danub; 2007 Dec; 19(4):367-9. PubMed ID: 18000491
[TBL] [Abstract][Full Text] [Related]
17. Duration of untreated psychosis and proton magnetic resonance spectroscopy (1H-MRS) findings in first-episode schizophrenia.
Galińska B; Szulc A; Tarasów E; Kubas B; Dzienis W; Czernikiewicz A; Walecki J
Med Sci Monit; 2009 Feb; 15(2):CR82-88. PubMed ID: 19179972
[TBL] [Abstract][Full Text] [Related]
18. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia.
Bustillo JR; Rowland LM; Jung R; Brooks WM; Qualls C; Hammond R; Hart B; Lauriello J
Neuropsychopharmacology; 2008 Sep; 33(10):2456-66. PubMed ID: 18094668
[TBL] [Abstract][Full Text] [Related]
19. Interaction of hippocampal volume and N-acetylaspartate concentration deficits in schizophrenia: a combined MRI and 1H-MRS study.
Klär AA; Ballmaier M; Leopold K; Häke I; Schaefer M; Brühl R; Schubert F; Gallinat J
Neuroimage; 2010 Oct; 53(1):51-7. PubMed ID: 20541020
[TBL] [Abstract][Full Text] [Related]
20. Hippocampal 1H MRS in patients with bipolar disorder taking valproate versus valproate plus quetiapine.
Atmaca M; Yildirim H; Ozdemir H; Ogur E; Tezcan E
Psychol Med; 2007 Jan; 37(1):121-9. PubMed ID: 17094813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
